Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: May 10, 2021
Reporting Period: This filing announces financial results for the three months ended March 31, 2021. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It serves solely to notify the market of the issuance of the Q1 2021 financial results press release.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a standard disclaimer stating that the information in this Current Report and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 10, 2021) for actual Q1 2021 financial figures.
- Verify the specific revenue and net loss figures for the three months ended March 31, 2021, as they are not listed in the 8-K cover page.
- Check the press release for any updates on clinical trial progress or regulatory milestones, which are typical for Omeros Corporation.
- Confirm cash position and burn rate details from the full financial statements referenced in the exhibit.